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Purpose: Relative costs and utilization-related outcomes of a fluticasone propionate 
250 µg + salmeterol 50 µg combination (FSC), tiotropium bromide, and ipratropium as 
initial maintenance therapy in COPD have not been compared in a commercially-insured 
population.
Methods: This retrospective, observational cohort study used health care claims data from 
January 2004 to June 2009 from a large administrative database for patients aged $40 years 
with COPD. Time-to-first COPD-related health care event beginning 30 days following therapy 
initiation with FSC (n = 16,684), ipratropium alone or in fixed dose combination with albuterol 
(n = 14,449), or tiotropium (n = 12,659) was estimated using Cox proportional hazard models 
that controlled for differences in patient demographic characteristics, health care utilization, 
and comorbidities at baseline. Mean adjusted costs and numbers of COPD-related health care 
encounters and prescription medication fills were compared among patients with 12 months of 
follow-up (FSC, n = 12,595; ipratropium, n = 10,617; tiotropium, n = 9126).
Results: With FSC as the reference, risk for a COPD-related hospitalization and/or emer-
gency department visit was significantly higher for ipratropium (hazard ratio [HR] 1.64, 95% 
confidence interval [CI] 1.50–1.79) and tiotropium (HR 1.29, CI 1.17–1.41). Mean adjusted 
12-month COPD-related total health care costs were lower for FSC ($2068, standard deviation 
[SD] $1190) than for ipratropium ($2841, SD $1858) and tiotropium ($2408, SD $1511, both 
P , 0.05). Mean number of COPD-related hospitalizations, emergency department visits, and 
outpatient visits associated with an oral corticosteroid or antibiotic were also lower for FSC 
than for ipratropium and tiotropium (all P , 0.05).
Conclusions: In this retrospective “real-world” observational sample of COPD patients, 
initiating treatment with FSC was associated with significantly better clinical and economic 
outcomes compared with short- and long-acting anticholinergic therapy. Consistent with the goal 
of preventing and reducing exacerbations advocated by global guidelines, the findings suggest 
that initiation of maintenance treatment with FSC may afford clinical benefits at a lower cost 
than anticholinergic treatment.
Keywords: chronic obstructive pulmonary disease, Advair®, tiotropium, ipratropium,   utilization, 
costs
Introduction
The use of appropriate medications for the treatment of chronic obstructive pulmo-
nary disease (COPD) is essential to improve patient quality of life and minimize the 
substantial burden of illness that COPD places on the health care system. The grow-International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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ing   population of individuals with COPD, comprising an 
estimated 24 million adults in the US, costs the nation 
approximately $42.6 billion each year, including $26.7 bil-
lion in direct costs and $15.9 billion in indirect costs.1,2 In 
addition, because COPD is a systemic disease, the presence 
of COPD-related comorbidities increases as the disease pro-
gresses, adding significantly to the disease burden.
Maintenance therapies for COPD that are recommended 
in widely accepted clinical guidelines include long-acting 
beta-agonists (LABAs) alone, inhaled corticosteroids (ICS) 
alone, ICS plus LABA, and anticholinergic agents.3,4 In 
various COPD populations, the combination of ICS plus 
LABA for maintenance therapy, including the combination 
medication of fluticasone propionate 250 µg + salmeterol 
50 µg (FSC), has been associated with a significantly lower 
risk for COPD-related hospitalizations, emergency depart-
ment visits, and health care costs compared with ipratropium, 
a short-acting anticholinergic.5–11 Tiotropium bromide, a 
long-acting anticholinergic, also has been shown to reduce 
exacerbations and COPD-related hospitalizations compared 
with ipratropium.12,13
To our knowledge, no studies have directly compared 
both the clinical and economic outcomes of these three 
maintenance therapies, in particular FSC and tiotropium, 
in a population of commercially-insured COPD patients, 
although Dalal et al reported an observational study compar-
ing economic outcomes for FSC, ipratropium, and tiotropium 
in a Medicare-eligible population.8 The purpose of this study 
was to describe and compare the health care utilization and 
cost outcomes in a patient population aged 40 years and 
older receiving FSC, a short-acting anticholinergic, or a 
long-acting anticholinergic as initial maintenance therapy for   
COPD.
Methods
In this retrospective, observational cohort study, clinical and 
economic COPD-related outcomes were evaluated in patients 
with COPD who received one of three medications for initial 
maintenance therapy for COPD, ie, FSC 250 µg/50 µg, ipra-
tropium alone or in fixed dose combination with albuterol 
(hereafter referred to as “ipratropium”), or tiotropium.
Data source
Administrative data for January 1, 2002 through June 30, 
2009 were obtained from the IMS LifeLink Health Plan 
Claims Database (IMS Health, Watertown, WA), which con-
tains enrollment and demographic data, health care facility 
and professional services claims (“medical” claims), and 
outpatient pharmacy claims from more than 70 US health 
plans covering more than 40 million patients. The dataset 
had been deidentified in compliance with the patient pri-
vacy regulations of the US Health Insurance Portability and 
Accountability Act. Facility claims in the LifeLink database 
include date of service, service location, and International 
Classification of Diseases, 9th Edition, Clinical Modification 
(ICD-9-CM) diagnosis and procedure codes. Professional 
service claims include date of service, service location, and 
Current Procedural Terminology, Version 4 (CPT-4) proce-
dure codes. Pharmacy claims include the National Drug Code 
and dispensing date; in addition, quantity and number of 
therapy days dispensed are provided by most health plans in 
the database. Most health care claims include billed charges; 
charges are imputed for claims with missing charges due to 
capitation arrangements. Enrollment, demographic, medical 
claims, and pharmacy claims for a given individual are linked 
using a unique encrypted identifier.
study sample
The study sample comprised patients who were naïve to 
maintenance treatment. Potentially eligible patients were 
enrolled in a health plan between January 1, 2004 and 
June 30, 2009, and had an initial pharmacy claim for one 
of the maintenance therapies (FSC, ipratropium, or tiotro-
pium) between July 1, 2004 and March 30, 2009. The initial 
claim date was designated the index date. Eligible patients 
also met the following criteria: age 40 years or older on the 
index date; had a primary or secondary diagnosis of COPD 
(ie, at least one emergency department visit, one hospital-
ization, or two outpatient visits with a primary or secondary 
ICD-9-CM code of 491.xx, 492.xx, or 496.xx during the 
baseline period); had at least one pharmacy claim for an 
initial maintenance therapy medication (including the index 
claim) in the follow-up period; had at least six months of 
continuous enrollment prior to the index date (the “baseline 
period”); and had 3–12 months of continuous enrollment 
after the index date (the “follow-up period”) to be eligible 
for the “risk population” analysis and had at least 12 months 
of continuous enrollment after the index date to be eligible 
for the utilization and cost population (“cost population”)   
analysis.
Patients were excluded if they had: a pharmacy fill 
for a study medication (FSC, ipratropium, or tiotropium), 
budesonide/formoterol, ICS alone, or LABA alone during 
the baseline period; a pharmacy fill for an alternate initial 
maintenance therapy medication within 60 days of the index 
date; or a primary or secondary diagnosis of respiratory tract International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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cancer (larynx, trachea, or pleura; ICD-9-CM codes 161, 
161.X, 162, 163, 163.X, 231, 231.X) during the baseline 
period. To remove outliers, patients were excluded if there 
was evidence they had more than 30 fills for the initial main-
tenance therapy medication in a 12-month postindex period 
or if the cost per 30-day fill of the initial maintenance therapy 
medication was more than five times the interquartile range 
above the 75th percentile (a variation on the Tukey outlier 
test of 1.5 times the interquartile range).14
Analysis
Demographic information and utilization records in the 
baseline period were used to characterize the cohorts, and 
utilization records in the follow-up period were used to 
evaluate outcomes.
The measured outcome in the risk population analysis 
was the time-to-first health care event following initia-
tion of maintenance therapy. Health care events evaluated 
were COPD-related outpatient visits with an antibiotic or 
oral corticosteroid prescription within 10 days of the visit, 
emergency department visit, hospitalization, and emergency 
department visit/hospitalization (combined endpoint). Out-
comes evaluated in the cost population analysis were mean 
health care utilization, unadjusted costs, and adjusted costs. 
The categories of health care utilization were COPD-related 
outpatient visits, emergency department visits, hospitaliza-
tions, and outpatient pharmacy. In addition, we examined a 
combined endpoint of hospitalization/emergency department 
visit, and for COPD-related outpatient visits we separately 
examined visits associated with a prescription fill for an oral 
corticosteroid or antibiotic within 10 days of the visit. The 
categories of costs analyzed in the cost population were medi-
cal costs, pharmacy costs, and total costs. In the analyses of 
both the cost and risk populations, an emergency department 
visit that resulted in an inpatient admission was not counted 
in the emergency department visit category in order to avoid 
double counting of episodes of care. However, the costs of 
these inpatient-linked emergency department visits were 
included when calculating total admission costs in order to 
avoid underestimation of health care costs.
Cox proportional hazard models were used to assess the 
risk of COPD exacerbations in the FSC, ipratropium, and 
tiotropium cohorts of the risk population. Kaplan–Meier 
survival curves for time-to-first-hospitalization/emergency 
department visit/outpatient visit (combined endpoint) were 
also modeled. Outcomes were assessed with follow-up start-
ing 30 days postindex date to ensure patients were allowed 
adequate exposure to the study medication before attributable 
outcomes were assessed. Patients lost to follow-up were 
censored. The models adjusted for age, gender, geographic 
region, baseline comorbidities, and utilization; factors signifi-
cant at P # 0.20 and affecting more than 2% of any cohort 
or deemed clinically meaningful were included as covariates. 
Appropriate model fit statistics and assumptions were evalu-
ated and assessed. Sensitivity analyses were conducted (results 
not shown) in which the outcomes were assessed beginning 
day 1 postindex date, and, in addition to censoring patients 
lost to follow-up, patients who filled a prescription for an 
alternative initial maintenance therapy medication prior to the 
health care event or who filled a prescription for budesonide/
formoterol, ICS alone, LABA alone, leukotriene modifier, or 
methylxanthine prior to the event were censored.
For the cost population, the mean number of COPD-related 
health care utilization events, mean unadjusted costs, and 
mean adjusted costs were calculated. Costs were inflated to 
2009 dollars on a monthly basis using the medical care portion 
of the consumer price index. Generalized linear models with a 
log-link and gamma family distribution were used to estimate 
predicted (adjusted) annual costs. The model controlled for 
differences between the cohorts in age, gender, treatment, 
comorbidities, and COPD-related health care utilization at 
baseline. Both absolute adjusted costs and cost differences are 
reported. The reported absolute adjusted costs are predicted 
values from the gamma regression models, with significance 
for mean differences calculated using Wald Chi-square test. 
Bootstrapping using the percentile method with 1000 sample 
simulations was used to estimate 95% confidence intervals 
(CI) for mean adjusted cost differences.
Demographic and other baseline characteristics of the 
cohorts are described as counts and percentages for cat-
egorical variables and measures of central tendency (mean 
or median and standard deviation [SD]) for continuous vari-
ables. P values were calculated using the Chi-square test for 
frequencies and t-test for continuous variables; the Wilcoxon 
rank sum test was used for differences in costs. Statistical 
tests were two-sided, with an α-level of 0.05 for statistical 
significance. All analyses were conducted using SAS version 
9.1.3 or 9.2 for Windows (SAS Institute, Cary, NC).
Results
risk analysis
A total of 43,792 subjects met the inclusion criteria for the 
risk population; 16,684 in the FSC cohort, 14,449 in the 
ipratropium cohort, and 12,659 in the tiotropium cohort 
(Figure 1). Mean age of the cohorts at baseline ranged from 
62.8 to 65.2 years (Table 1). Selected comorbidities are International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Subjects with a COPD diagnosis and
prescription drug fill for Initial Maintenance
Therapy (IMT) between 6/30/02 and 6/30/09:
268,477     
Subjects age 40+ who met enrollment criteria
and were naïve to maintenance therapy
at baseline:
91,282 
Subjects with an IMT index date on
or after 7/1/2004:
72,825  
Subjects with a COPD diagnosis on or prior to
IMT index date and no ICS or LABA within
 60 days following index date:
59,618 
Risk Population:
Subjects who met IMT cost and days supply
criteria and had no ICS or LABA use at
baseline:
43,792
(FSC = 16,684, IPR = 14,449, TIO = 12,659)  
Cost Population:
Subjects with at least 12 months of follow-up:
32,338
(FSC = 12,595, IPR = 10,617, TIO = 9126) 
Figure 1 Patient selection.
shown in Table 1. The FSC cohort had a higher prevalence 
of asthma than the other two groups, the ipratropium cohort 
had a higher prevalence of depression than the FSC cohort, 
and both the ipratropium and tiotropium cohorts had a 
higher prevalence of congestive heart failure and hyperten-
sion than the FSC cohort (all P , 0.05). The FSC cohort 
also had the highest percentage of patients with a claim for 
a short-acting beta-agonist at baseline (25.0% for FSC ver-
sus 14.1% for ipratropium and 20.3% for tiotropium; both   
P , 0.05).
Using the FSC cohort as the reference, both the ipra-
tropium and tiotropium cohorts had significantly higher 
time-to-first event hazard ratios (HRs) for health care utili-
zation events (Table 2). In the ipratropium cohort, the HRs 
ranged from 1.39 for an outpatient visit with antibiotic to 
1.78 for an emergency department visit. The increased risks 
for tiotropium were slightly lower, ranging from 1.29 for a 
hospitalization and/or emergency department visit (combined 
endpoint) to 1.49 for an outpatient visit with oral corticoster-
oids. In the sensitivity analyses that were conducted using a 
different follow-up start date (ie, beginning day 1 rather than 
day 30 after the index date) or different patient censoring 
criteria, significantly higher risks remained for the ipratro-
pium and tiotropium cohorts compared with the FSC cohort 
for all four utilization events. The Kaplan–Meier survival 
curves for any COPD-related health care utilization event are 
shown in Figure 2. The curves further illustrate that, on aver-
age, the ipratropium and tiotropium groups, in comparison 
with the FSC group, had shorter times between initiation of 
therapy and the occurrence of a COPD-related health care   
event.
Cost and utilization analysis
A total of 32,338 patients met the inclusion criteria for 
the cost population, comprising 12,595 in the FSC cohort, 
10,617 in the ipratropium cohort, and 9126 in the tiotropium 
cohort (Figure 1). The demographic, clinical, and other base-
line characteristics of this cost population (data not shown) 
are similar to those of the risk population.
A total of 8.9% of patients had either a COPD-related 
emergency department visit or hospitalization and 34.2% 
had a COPD-related outpatient visit in the follow-up period; 
2.7% had an outpatient visit with oral corticosteroids and 
4.9% had an outpatient visit with antibiotics. Mean health care 
utilization during the follow-up period, including the mean 
medication possession ratio for each cohort’s initial mainte-
nance therapy medication, is shown in Table 3. The medication 
possession ratio represents the number of therapy days covered 
by the dispensed medication fills divided by the days in the 
observation period. No cohorts had a mean medication posses-
sion ratio above 50% for the COPD maintenance medication. 
The medication possession ratios were lowest for the iprat-
ropium cohort (22%) and highest for the tiotropium cohort 
(41%). To ensure that the index pharmacy claim represented 
maintenance therapy initiation rather than a therapy switch, 
patients in this study could not have a prescription claim for 
an alternate initial maintenance therapy medication within 
60 days of initial maintenance therapy initiation. After the 
60-day period, approximately 13% of patients in each cohort 
had pharmacy claims for an alternate maintenance therapy 
(patients were followed within their assigned cohort regard-
less of changes in regimen after 60 days, in concordance with International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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Table 1 Demographic and clinical characteristics of study population (“risk population”)
FSC 
(n = 16,684)a
Ipratropium  
(n = 14,449)a
Tiotropium  
(n = 12,659)a
Age, mean (sD) 62.8 (12.0) 65.2 (12.6)b 64.5 (11.3)b
Female 9127 (54.7) 7143 (49.4)b 5862 (46.3)b
$12 months follow-up 12,595 (75.5) 10,617 (73.5)b 9126 (72.1)b
selected comorbid conditions:
Asthma 4077 (24.4) 1951 (13.5)b 1510 (11.9)b
Congestive heart failure 1850 (11.1) 2967 (20.5)b 1945 (15.4)b
Depression 1153 (6.9) 1184 (8.2)b 848 (6.7)
hypertension (uncomplicated) 8098 (48.5) 7627 (52.8)b 6484 (51.2)b
COPD-related utilization in preindex period:
Outpatient visit 5173 (31.0) 4426 (30.6) 5401 (42.7)b
Outpatient visit with oral corticosteroid 509 (3.1) 669 (4.6)b 353 (2.8)
Outpatient visit with antibiotic 865 (5.2) 1030 (7.1)b 692 (5.5)
emergency department visit 408 (2.4) 609 (4.2) 336 (2.7)
hospitalization 811 (4.9) 1428 (9.9)b 895 (7.1)b
emergency department visit or hospitalization 1184 (7.1) 1983 (13.7)b 1184 (9.4)b
short-acting β-agonist  4178 (25.0) 2044 (14.1)b 2572 (20.3)b
health care costs in preindex period, mean (sD):
Medical 993 (16,589) 2162 (12,722)b 1459 (12,439)b
Pharmacy 49 (165) 32 (135)b 33 (106)b
Total 1042 (16,589) 2193 (12,721)b 1492 (12,439)b
Notes: aAll figures are n (%) unless otherwise noted; bP , 0.05 for difference with FsC cohort.
Abbreviations: COPD, chronic obstructive pulmonary disease; FSC, fluticasone propionate/salmeterol combination.
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Figure  2  Time  to  any  eventa  Kaplan–Meier  survival  curve:  Initial  maintenance 
therapy with FsC, tiotropium, or ipratropium.b,c
Notes:  aAny COPD-related outpatient visit, emergency department visit or inpatient 
admission;  bFollow-up period ranged from 3 to 12 months;  cFor determining the 
survival function, follow-up began on day 30 following initiation of initial maintenance 
therapy. 
Abbreviation: COPD, chronic obstructive pulmonary disease; FSC, fluticasone 
propionate/salmeterol combination.
Table  2  results  from  Cox  proportional  hazard  analyses 
examining risk of COPD exacerbations between study cohorts 
(“risk population”)
COPD-related  
utilization
Ipratropiuma  
n = 14,449
Tiotropiuma  
n = 12,659
Hazard ratio (95% confidence 
interval)b,c
Outpatient visit with  
oral corticosteroid 
1.65 (1.41–1.94) 1.49 (1.26–1.76)
Outpatient visit with  
antibiotic 
1.39 (1.23–1.57) 1.33 (1.17–1.51)
emergency department  
visit 
1.78 (1.59–2.00) 1.33 (1.17–1.51)
hospitalization or emergency  
department visit
1.64 (1.50–1.79) 1.29 (1.17–1.41)
Notes: aWith reference to the FsC cohort; bThe postindex date period ranged from 
3 to 12 months; follow-up began on day 30 following initiation of initial maintenance 
therapy; cAdjusted for age, gender, treatment, and comorbidities and COPD-related 
health care utilization at baseline. 
Abbreviations: COPD, chronic obstructive pulmonary disease; FSC, fluticasone 
propionate/salmeterol combination.
an intent-to-treat approach). COPD-related hospitalizations, 
emergency department visits, and outpatient visits associated 
with an antibiotic or oral corticosteroid prescription medica-
tion fill can be considered as a reasonable proxy measure of 
COPD exacerbations. These encounters consistently occurred 
more often in the ipratropium and tiotropium cohorts than in 
the FSC cohort (all P , 0.05). Unadjusted mean costs are 
also shown in Table 3; total COPD-related costs for the FSC 
cohort ($2018) were lower than for the ipratropium ($2809) 
and tiotropium ($2453) cohorts.
Mean adjusted 12-month COPD-related total health care 
costs also were lower for FSC compared with ipratropium or 
tiotropium (both differences P , 0.05) (Figure 3). The differ-
ences in mean adjusted costs are shown in Table 4; compared 
with FSC, total costs were $773 higher for ipratropium and 
$339 higher for tiotropium.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Table 3 Unadjusted COPD-related health care utilization and costs associated with initial maintenance therapies in the one-year 
follow-up period (“cost population”)
FSC  
(n = 12,595)
Ipratropium 
(n = 10,617)
P valuea Tiotropium 
(n = 9126)
P valuea 
COPD medication utilization
Medication possession ratio for 
primary initial maintenance  
therapy medication (mean, sD)
32% (28%) 22% (23%) ,0.001 41% (33%) ,0.001
Alternate maintenance therapy, n (%)
FsC na 795 (7.5) – 839 (9.2) –
Ipratropium 713 (5.7) na – 461 (5.1) ,0.001
Tiotropium 956 (7.6) 790 (7.4) ,0.876 na –
Any alternate maintenance therapy  1571 (12.5) 1367 (12.9) 0.560 1208 (13.2) 0.187
SABA prescription fills, mean (SD) 1.44 (2.90) 0.81 (2.45) ,0.001 1.48 (3.13) 0.4029
COPD-related health care utilization, n (%)
hospitalization 446 (3.5) 651 (6.1) ,0.001 413 (4.5) ,0.001
Outpatient visit w/oral corticosteroid 261 (2.1) 354 (3.3) ,0.001 262 (2.9) ,0.001
Outpatient visit with antibiotic 490 (3.9) 617 (5.8) ,0.001 478 (5.2) ,0.001
emergency department visit 450 (3.6) 778 (7.3) ,0.001 427 (4.7) ,0.001
Outpatient visit 3615 (28.7) 3788 (35.7) ,0.001 3661 (40.1) ,0.001
hospitalization/emergency department visit 819 (6.5) 1284 (12.1) ,0.001 764 (8.4) ,0.001
COPD-related health care utilization, mean (SD)
Outpatient visit 0.76 (2.24) 1.28 (3.13) ,0.001 1.26 (3.14) ,0.001
Outpatient visit with oral corticosteroid 0.03 (0.27) 0.05 (0.33) ,0.001 0.04 (0.28) 0.0153
Outpatient visit with antibiotic 0.05 (0.32) 0.08 (0.40) ,0.001 0.07 (0.37) ,0.001
emergency department visit 0.04 (0.28) 0.09 (0.37) ,0.001 0.06 (0.28) 0.0044
hospitalization 0.04 (0.24) 0.08 (0.34) ,0.001 0.06 (0.29) 0.0011
hospitalization/emergency department visit 0.09 (0.40) 0.17 (0.55) ,0.001 0.11 (0.44) ,0.001
COPD-related health care costs, mean (SD)
Medicalb $1058 ($7545) $2179 ($12,094) ,0.001 $1485 ($9489) 0.001
Pharmacyc $960 ($1040) $630 ($945) ,0.001 $968 ($949) 0.551
Total $2018 ($7658) $2809 ($12,219) ,0.001 $2453 ($9588) 0.001
Notes:  aFor difference with FsC cohort; bMedical costs include outpatient, emergency department, and inpatient care; cPharmacy costs include all outpatient prescription 
medication costs (includes cost of study medication as well as other COPD medications dispensed after the 60-day postindex date window). 
Abbreviations: FSC, fluticasone propionate/salmeterol combination; na, not applicable; SABA, short-acting beta-agonist; SD, standard deviation; COPD, chronic obstructive 
pulmonary disease.
Discussion
Previous studies have examined outcomes and costs asso-
ciated with FSC, ipratropium, or tiotropium in different 
patient populations, but this is the first study to compare 
all three maintenance therapies in a commercially-insured 
COPD population in a real-world setting. In the absence 
of head-to-head clinical trials, observational studies can 
be valuable from the health plan perspective. In this retro-
spective, observational study of initial maintenance therapy 
for COPD we used medical and pharmacy claims data for 
32,338 patients (the “cost population”) and found lower 
health care utilization rates associated with FSC compared 
with ipratropium or tiotropium. In accord with the generally 
lower utilization rates, COPD-related health care costs also 
were lower for FSC than for ipratropium and tiotropium, 
both total costs and component costs, with higher pharmacy 
costs of FSC therapy more than offset by lower medical 
costs. Additionally, a time-to-event proportional hazard 
analysis of 43,792 patients (the “risk population”) indicated 
that those receiving ipratropium or tiotropium for initial 
maintenance therapy had a higher risk for earlier occurrence 
of exacerbations as indicated by COPD-related health care 
events. Compared with FSC, use of tiotropium was associ-
ated with a 49% higher risk for outpatient visit with an oral 
corticosteroid prescription medication fill, a 33% higher 
risk for outpatient visit with an antibiotic fill, a 33% higher 
risk for emergency department visit, and a 29% higher risk 
for a COPD-related hospitalization/emergency department 
visit combined endpoint. Adherence to therapy was not high 
in any of the cohorts, and was similar to values reported in 
previous studies.5,9 During the study period, FSC patients 
had enough prescription fills to provide therapy for only International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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A
Total health care costs Pharmacy costs
$1,076
$972
$2,068
$985
$2,408 $2,481
$614
$2,841
$1,419
$0
$500
$1,000
$1,500
$2,000
$2,500
$3,000
$3,500
$4,000
Medical costs
FSC Tiotropium Ipratropium
FSC Tiotropium Ipratropium
P < 0.001
P < 0.001
P = 0.004
P < 0.001
P < 0.001
P < 0.001
B
$159
$932
$1,076
$258
$2,314
$1,419
$274
$1,160
$2,481
$0
$500
$1,000
$1,500
$2,000
$2,500
$3,000
Outpatient costs Inpatient and emergency
department costs
Total medical costs
P < 0.001 P < 0.001
P < 0.001
P < 0.001
P < 0.001
P < 0.001
Figure 3 Predicted (adjusted) 12-month COPD-related health care costs (in 2009 $Us) associated with different initial maintenance therapies (data from the “cost population”).a 
A) COPD-related health care costs; B) Breakdown of the medical component of COPD-related health care costs. 
Note:  aCosts were adjusted for age, gender, treatment, and comorbidities and COPD-related health care utilization at baseline. P-values are for differences between 
tiotropium and FsC, and between ipratropium and FsC.
Abbreviations: COPD, chronic obstructive pulmonary disease; FSC, fluticasone propionate/salmeterol combination.
32% of the 12-month follow-up period, tiotropium patients 
had enough for 41% of the period, and ipratropium patients 
had enough for just 22% of the period.
These findings are in general agreement with several prior 
studies of FSC and ipratropium as maintenance therapy for 
COPD.5–11 Rascati et al found that, compared with ipratro-
pium, combination ICS/LABA therapy was associated with a 
27% reduced risk for any COPD-related event in a cohort of 
Medicaid enrollees with COPD.11 An earlier analysis in a Med-
icaid population found a 35% lower risk for COPD-related 
hospitalization with ICS/LABA compared with ipratropium 
therapy.10 In an evaluation of a higher dosage of FSC (500 
µg/50 µg), a 45% lower risk for a COPD-related hospitaliza-
tion or emergency department visit with FSC compared with 
ipratropium was reported for a population aged 65 years and 
older.7 Others have reported a nonsignificant reduction in total 
health care costs, but a 41% reduced risk for COPD-related 
hospitalization or emergency department care with FSC 
compared with ipratropium.9 Additional research has found 
utilization and cost benefits are associated with tiotropium International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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compared with ipratropium. For example, a cost-effectiveness 
study of tiotropium versus ipratropium found lower exacer-
bation rates with tiotropium but an increased incremental 
cost-effectiveness ratio,12 and a randomized clinical trial of 
tiotropium versus ipratropium found that tiotropium was 
associated with fewer exacerbations and an increased time to 
first hospitalization.15 In a retrospective, observational study 
of an older population with COPD, patients aged 65 years and 
older who received tiotropium as initial maintenance therapy 
had a 19% increased risk (HR 1.19) for serious health care 
events (hospitalization or emergency department visit) in the 
12 months following therapy initiation compared with patients 
who received FSC.16 This is lower than the 29% (HR 1.29) 
increased risk seen in the somewhat younger population in the 
present study. In the older population study, mean total costs 
in the 12 months following therapy initiation were 16% lower 
in the FSC group than in the tiotropium group, which is the 
same percent reduction seen in the present study.
We believe our study is the first to compare FSC, iprat-
ropium, and tiotropium in terms of relative costs, utilization, 
and time-to-first-event risk in a population of COPD patients 
aged 40 years and older. Tiotropium and LABA are recom-
mended in clinical guidelines as first-line therapies, with the 
addition of ICS (or ICS/LABA) recommended for repeated 
exacerbations.4 In this population of maintenance-naïve 
patients, those receiving ICS/LABA were slightly younger 
at baseline than the patients receiving either a short-acting 
or long-acting anticholinergic agent. This study suggests 
that initial treatment with the ICS/LABA combination, FSC, 
results in improved costs and outcomes compared with anti-
cholinergic treatment using tiotropium or ipratropium.
This study has several strengths. One is the large sample 
size, which allowed a robust head-to-head comparison of 
three maintenance therapies. We ensured that the risk and 
cost populations studied were naïve to maintenance treat-
ment in order to assess exposure and outcomes adequately. 
An intent-to-treat approach was used to reflect real-world 
practice patterns. We required a 60-day postindex date win-
dow during which patients on one study medication could 
not receive an alternate study medication. This ensured that 
the treatment a patient was assigned to for analysis purposes 
did not represent merely a switch in therapy, but was in fact 
the intended maintenance regimen. After this window, an 
intent-to-treat approach was employed (ie, patients were 
followed regardless of adherence or changes in regimen). In 
the risk analyses, we captured outcomes beginning 30 days 
after therapy initiation. Immortal time bias, a problem in 
some survival analyses, does not apply to this analysis, 
because requirements for cohort entry, drug exposure, and 
the observable time available between cohort entry and the 
first outcome event were the same for all cohorts. In addi-
tion, to allay concerns about other bias that may have been 
introduced, we conducted sensitivity analyses in which 
time-to-event models captured outcomes beginning day 1 
following therapy initiation and analyses that incorporated 
the use of COPD-related medications other than the initial 
maintenance therapy medication prior to an event. Outcomes 
in these latter analyses were similar in both magnitude and 
statistical significance to the primary study model. We also 
accounted for differences in baseline characteristics between 
the cohorts by including these characteristics as covariates 
in multivariable models.
Some limitations of this study should be noted. This 
was an observational analysis using medical claims data. 
Because health care claims are limited by a lack of clinical 
data, COPD severity could not be fully characterized, and 
some clinical and patient characteristics that might have 
influenced physicians to provide a particular initial mainte-
nance therapy could not be ascertained. It was observed that 
a higher percentage of tiotropium patients in the baseline 
period had a primary, rather than secondary, diagnosis of 
COPD (as indicated by diagnosis codes in claims data) 
compared with FSC and ipratropium patients, possibly 
indicating these patients had more severe, symptomatic, or 
otherwise more clinically recognizable disease. Although 
our model controlled for these baseline differences, some 
residual confounding may be present. It is also possible that 
physicians are less likely to prescribe FSC than ipratropium 
Table  4  Adjusted  differences  in  COPD-related  costs  in  the   
one-year follow-up period (“cost population”)a
COPD-related  
health care
Difference in adjusted costs relative 
to FSC, $US (95% CI)
Ipratropium  
(n = 10,617)
Tiotropium  
(n = 9126)
Medicalb 1405 (1329,1490) 344 (288,401)
Pharmacyc -358 (-369,-346) 14 (1,26)
Totald 773 (716,829) 339 (287,395)
Notes: aCosts and odds ratios were adjusted for age, gender, treatment and other 
covariates; bMedical costs include COPD-related outpatient, emergency department, 
and inpatient care; cPharmacy costs include all outpatient prescription medication costs 
(includes costs of study medication as well as other COPD medications dispensed 
after the 60-day postindex date window); dCosts are not cumulative because individual 
models were used to predict each component. CI were generated by bootstrapping 
1000 simulated samples. 
Abbreviations:  CI,  confidence  intervals;  COPD,  chronic  obstructive  pulmonary 
disease; FSC, fluticasone propionate/salmeterol combination.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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or tiotropium for patients with relatively more comorbidi-
ties; our data show that the FSC cohort had a somewhat 
lower mean prevalence of several comorbidities than the 
ipratropium and tiotropium cohorts. Thus, it is possible that 
the utilization and cost differences seen are due to under-
lying differences in the health status of the cohorts rather 
than to the therapeutic agent. In addition, some confound-
ing may have occurred with respect to the particular initial 
maintenance therapy medication a patient received. While 
patients were not allowed to have a prescription fill for an 
alternative initial maintenance therapy medication within 
the first 60 days following initiation of therapy, they could 
have such a fill thereafter, and approximately 13% of each 
group did fill a prescription for an alternate initial mainte-
nance therapy medication. However, because this crossover 
was similar in all three groups, any potential bias from 
crossover is likely to be minimal. Prior research has found 
that 95% of COPD cases identified from claims data are 
confirmed by information contained in the patient’s medi-
cal record, such as pulmonary function tests, chest x-ray, 
smoking history, and physical findings.17 Nonetheless, the 
possibility remains that in some cases asthma may have been 
misclassified as COPD (and vice versa) at the clinic level 
and the inaccuracy carried over into claims data. Finally, 
as noted earlier, the benefits of ICS/LABA combination 
therapy have been demonstrated in several studies, but 
recent studies have also investigated the efficacy of combin-
ing tiotropium and ICS/LABA therapy (triple therapy) in 
patients with severe COPD.18 Although triple therapy may 
provide additional benefits, investigation of this form of 
combination treatment for severe COPD was beyond the 
scope of our study.
To our knowledge, the present study is the first to com-
pare health care utilization and costs between these three 
maintenance therapies for COPD in a commercially-insured 
patient population. We found that adjusted COPD-related 
utilization and costs were lower with FSC than with either 
ipratropium or tiotropium. In addition, time-to-first-event 
risks were improved with FSC compared with other main-
tenance therapies. These findings suggest that initial main-
tenance therapy with FSC may offer clinical and cost benefit 
in comparison with short- and long-acting anticholinergics. 
Considering that the primary goal of COPD management is 
the prevention and reduction of exacerbations and that this 
study shows that patients receiving FSC had lower risk for 
COPD exacerbations, maintenance treatment with FSC may 
offer some clinical benefits.
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